WO2003026685A1

WO2003026685A1 - Agents improving lipid metabolism in liver

Info

Publication number: WO2003026685A1
Application number: PCT/JP2002/009570
Authority: WO
Inventors: Nobuhiro Fukuda; Masanobu Sakono; Toshihiro Nakamori; Hitoshi Furuta; Michihiro Sugano
Original assignee: Fuji Oil Company, Limited
Priority date: 2001-09-21
Filing date: 2002-09-18
Publication date: 2003-04-03
Also published as: JPWO2003026685A1

Abstract

It is intended to provide agents improving the lipid metabolism in the liver. This object is achieved by providing lipid metabolism improving agents containing an enzymatic digestion product of soybean protein whereby the triglyceride content in the liver can be lowered and the secretion of triglycerides in the liver can be inhibited. By using the above agents, β-oxidation in the liver can be accelerated, i.e., the digestion of fatty acids can be accelerated and thus fat accumulated as body fat is consumed, thereby achieving an effect of lessening body fat.

Description

Drugs for improving lipid metabolism in the liver

TECHNICAL FIELD The present invention relates to an agent for improving lipid metabolism of hepatic uchida, which promotes oxidation in the liver to decrease triglyceride content in the liver and suppresses secretion of triglyceride from the liver.

Several proteins and their hydrolysates (peptides) are known as lipid metabolism improvers. It is known that plant proteins, particularly soy protein, are superior to animal proteins in improving the lipid metabolism of proteins. As for these protein hydrolysates (peptides), those derived from various proteins are known as follows, and their effects are various.

First, examples of lipid improving agents other than the hydrolyzate of soybean protein include, for example, JP-A-52-83186 (new polypeptide), JP-A-04-149137 (diet agent), and JP-A-06-183. Japanese Patent Application Laid-Open No. 211690/2001 (Feedings for blood lipid suppression derived from casein), Japanese Patent Application Laid-Open No. 11-80006 (Lipid Absorption Inhibitor)

2000-264845 (fish-derived cholesterol lowering agent), JP-A 2000-228967 (lipid metabolism processed food), JP-A

2001-2577 (lipid metabolism improving agent derived from royal jelly), Japanese Patent Application Laid-Open No. 2001-57868 (lipid derived from livestock processing wastewater) JP-A-2001-57869 (material for improving obesity and diet), JP-A-2001-58955 (bioactive peptide release preparation), JP-A-08-157389 (High triglyceride) Japanese Patent Application Laid-Open No. 09-157290 (Cholesterol-reducing peptide), Japanese Patent Application Laid-Open No. 09-255698 (Peptide for suppressing increase in blood triglyceride concentration), Japanese Patent Application Laid-Open No. 07-188284 (Hematology) Peptides that inhibit an increase in medium triglyceride concentration) are known.

On the other hand, soy protein is not only excellent in nutritional properties among vegetable proteins, but also has various physiological activities in recent years, and is a food material that has attracted attention as a physiological function agent. The effect of lowering body fat percentage on soybean protein has already been confirmed, but its mechanism is not known other than to suppress the activity of fatty acid synthase in the liver (Iriya et al. J. Nu tr., 126, 380, 19996).

On the other hand, there are various known effects of improving the lipid metabolism of a peptide obtained by hydrolyzing a protein, but nothing is known about the effect of improving the metabolism of the liver itself.

For example, Japanese Patent Application Laid-Open No. 5-87052 states that lipid metabolism-improving agents have the effect of lowering the fat content and the amount of fat droplets in the liver. This is because the fat content to be absorbed is reduced to suppress the activity, and the fat content in the serum is reduced. This is not the effect of changing the lipid metabolism activity itself in the liver.

In addition, Tridari in the liver for soy protein enzyme digests The decrease in cerium content is described in Japanese Patent Application Laid-Open No. 4-18772 as quotation data, but it only recognizes the effect.

Japanese Patent Application Laid-Open No. H04-149137 (diet) is known as a protein-hydrolyzed low molecular weight peptide, which is composed mainly of dipeptides and tripeptides, and has fat accumulation. It mentions the inhibitory effect and the weight gain inhibitory effect, but does not mention the effect of improving liver metabolism.

Japanese Patent Application Laid-Open No. 10-203994 discloses a bioactive composition in which a soybean protein-degraded peptide having a molecular weight of 500 to 5000 increases neutral fat in blood and HDL-cholesterol. However, there is no mention of the effect of improving lipid metabolism in the liver.

On the other hand, the present applicant has continuously studied the physiological action of soybean protein hydrolyzate (peptide mixture), particularly on lipid metabolism. For example, as disclosed in Japanese Patent Publication No. Hei 7-025796, a soybean protein hydrolyzate (oligopeptide mixture) suppresses an increase in cholesterol in the blood, Japanese Patent Application Laid-Open No. 1-269456, and Japanese Patent Application Laid-Open No. 3-272694. As disclosed in the gazette, it has been disclosed that it is involved in the metabolism of cholesterol and triglycerides. However, among lipid metabolism, the mechanism of lowering triglyceride was not clear.

The present invention is intended to reduce the triglyceride content in the liver by increasing trioxidation in the liver, and to improve the lipid metabolism in the liver by suppressing the secretion of tridaliceride from the liver. It was completed and put out. Purpose of the invention

The present invention enhances lipid metabolism in the liver, in particular, increases trioxidation in the liver to reduce triglyceride content in the liver and suppresses triglyceride secretion from the liver, among lipid metabolism improvements. The aim was to improve lipid metabolism in the liver. Disclosure of the invention

In order to solve the above-mentioned problems, the present inventors have conducted research using a liver perfusion system extracted from the liver, and, while continuing intensive research, have found that soy protein is higher than casein, and that soy protein is higher than casein. It has been found that the enzymatically degraded product does not change the amount of fatty acid absorption itself and suppresses the accumulation and secretion of triglyceride in the liver.

That is, the present invention is an agent for improving lipid metabolism in the liver, comprising an enzymatically decomposed product of soybean protein as an active ingredient. Lipid metabolism by this agent enhances -6-oxidation in the liver and lowers the content of tridaliceride in the liver, and in particular, lipid metabolism suppresses the secretion of triglyceride from the liver. The average peptide chain length of the enzyme hydrolyzate of soybean protein is preferably 2 to 20, more preferably 5 to 10. BEST MODE FOR CARRYING OUT THE INVENTION

The enzymatic degradation product of soybean protein, which is an active ingredient of the lipid metabolism improving agent of the present invention, will be described.

The enzyme decomposition product of soy protein used in the present invention can be obtained by decomposing soy protein with an enzyme. The enzyme digest of soy protein preferably has an average peptide chain length of 2 to 20 and more preferably an average peptide chain length of 5 to 10. The enzymatically degraded soybean protein having such an average chain length can increase the [3] oxidation in the liver and significantly reduce the triglyceride content in the liver. In addition, the enzymatically decomposed product of soybean protein having such an average chain length can suppress secretion of triglyceride from the liver.

An example of a method for producing an enzyme hydrolyzate of the present invention obtained by decomposing a soybean protein with an enzyme is shown below.

Enzymatic degradation products can be obtained by hydrolyzing soybean protein in an aqueous system (soybean protein slurry or solution) using an enzyme (proteolytic enzyme). As the soybean protein of the present invention, soymilk, concentrated soybean protein, isolated soybean protein, defatted soybean, soybean whey protein, or the like can be used as a material that can be obtained at a low cost. Among them, isolated soybean protein is preferable. The concentration of the soybean protein solution to be subjected to the enzyme treatment is suitably 1% by weight to 30% by weight, preferably 5 to 15% by weight, more preferably 8 to 12% by weight. Although a low concentration does not interfere with enzymatic decomposition, it is not preferable because the productivity is reduced. If the concentration of the soybean protein solution is too high, a large amount of enzyme is required to decompose sufficiently, probably because the polymerization of the degraded protein hydrolysates becomes stronger. Is not preferred.

The enzyme used in the present invention is suitably an enzyme containing a proteolytic enzyme (protease), and exoprotease or endprotease may be used alone or in combination, and may be of animal, plant or microbial origin. . Specifically, serine proteases (trypsin, chymotrypsin derived from animals, subtilisin derived from microorganisms, lipoxypeptidase, etc.), thiol proteases (papain, fusin, promelain, etc. derived from plants), carboxyproteases ( Animal-derived pepsin) can be used. More specifically, “Protin FN” derived from Aspergillus oryzae (manufactured by Daiwa Kasei Co., Ltd.), “actinase” derived from Streptomyces griseus (manufactured by Kaken Pharmaceutical Co., Ltd.), Examples include “ALALASE” (manufactured by Novozymes Japan Ltd.) and “Protin A” (manufactured by Daiwa Kasei Co., Ltd.) derived from Bacillus subtilis. In addition, examples of enzymes containing endprotease include "Puguchi Thease" (manufactured by Amano Pharmaceutical Co., Ltd.) and "Protin AC-10" (manufactured by Daiwa Kasei Co., Ltd.). "Proteases 11" (manufactured by Amano Pharmaceutical Co., Ltd.) can be mentioned as an example of the proteolytic enzyme containing the enzyme and the end protease. The hydrolysis conditions of the present invention vary somewhat depending on the type of protease used, but it is generally preferable to use an amount sufficient to hydrolyze soybean protein in the working pH range and working temperature range of the protease. When considering the use of salt-restricted diets (eg, tube feeding diets) with lipid metabolism improvers The pH is preferably 5 to 10, preferably 6 to 9, since salt formation due to neutralization can be reduced. The degree of hydrolysis is suitably an average peptide chain length of 2 to 20, preferably 5 to 10.

It is preferable to remove insolubles from the enzyme digest of soybean protein because the effect of promoting lipid metabolism is enhanced.

Means for separating and removing insoluble decomposed products from the enzyme-decomposed solution of soybean protein may be by means of a filter press, membrane separation, or other means, but the most common method is a combination of centrifugation and membrane separation.

When enzymatic digestion is performed under acidic conditions, for example, when the pH of the enzyme digestion solution of soybean protein is in the range of 3 to 8, in order to increase the separability at the time of this separation, it is necessary to increase the Is suitably set to 4 to 6.2, preferably 4.5 to 5.5. This is because insoluble matter including undegraded matter tends to agglomerate near the isoelectric point of soybean protein. Alternatively, an alkaline earth metal compound such as a salt or hydroxide of calcium or magnesium chloride or sulfate, or a protein flocculant such as sodium polyacrylate, alginic acid, or chitin chitosan may be added to the decomposition solution. Separability can be improved.

As described above, the enzymatically degraded soybean protein obtained by separating and removing the insoluble decomposed product from the enzymatically decomposed soybean protein solution promotes the oxidation of 3 in the liver than the enzymatically degraded product of soybean protein in an aqueous system. To reduce triglyceride content in the liver, and to suppress secretion of triglyceride from the liver. Excellent in improving lipid metabolism in the liver, which is preferable. The present invention is an agent for improving lipid metabolism in the liver, which contains an enzyme hydrolyzate of soybean protein produced as described above as an active ingredient. In the present invention, the mechanism of improving lipid metabolism is different from that of a conventional enzyme digest of a protein.

In the present invention, the mechanism for improving lipid metabolism is to increase i3 oxidation in the liver to reduce triglyceride content in the liver. In other words, the agent for improving lipid metabolism in the liver of the present invention is an agent for reducing triglyceride content in the liver. In the present invention, the lipid metabolism improving mechanism suppresses secretion of triglyceride from the liver. In other words, the agent for improving lipid metabolism in the liver of the present invention is a triglyceride secretion inhibitor from the liver.

Even if it is known that soybean protein is superior in improving lipid metabolism than animal protein, and if it is known that a conventional soybean protein enzymatic degradation product is superior in improving lipid metabolism, as in the present invention, Mechanism was not elucidated.

From the viewpoint of improving lipid metabolism, the present invention relates to an agent for decreasing triglyceride content in liver and an agent for inhibiting Z or triglyceride secretion from liver.

The agent for improving lipid metabolism in the liver of the present invention is a triglyceride reducing agent that is extremely safe and has no fear of side effects because it contains an enzyme-decomposed product of soybean protein-derived soybean protein as an active ingredient, and is mixed with various foods. It can be taken in drink form or tablet form. As it is a safe food ingredient, there is no adverse effect from overdose, and 0.5 g per person as a guide for daily intake A suitable amount is 50 g, preferably about 3 to 15 g. 〔Example〕

Hereinafter, embodiments of the present invention will be described with reference to examples. <Production Example 1> (Method for producing enzyme-decomposed product of soybean protein)

The following Example Soy Enzyme Decomposition D-1

30 kg of isolated soybean protein (Fuji Oil Co., Ltd., “New Fujipro I-R”) is converted to a 9% aqueous solution of pH 7.0, and 1.2 kg of proteolytic enzyme (Amano Pharmaceutical Co., Ltd., “Proteaze”) is added. After hydrolyzing at 60 ° C for 5 hours (15% TCA solubility: 85%), steam of 8 kg / cm2 pressure is blown into this solution, sterilized at 140 ° C for 7 seconds, and spray-dried to powder Let dry. The average chain length of D-1 was 6.

<Production Example 2> (Method for producing enzyme-decomposed product of soybean protein)

The following Example Soybean enzyme digest D-3

Isolate soybean protein (Fuji Oil Co., Ltd., “New Fuji Pro-R”) 30 parts by weight of 9% aqueous solution of pH 7.0, and proteolytic enzyme (Amano Pharmaceutical Co., Ltd., “Proteaze”) 1.2 After hydrolyzing at 60 ° C for 5 hours (15% TCA solubility: 85%), a high-speed centrifuge capable of continuous processing (SB-7, WESTFALIA

The sedimentation component was separated and removed by adjusting the feed rate at 100 liters Z to SEPARATOR. The obtained supernatant liquid was sterilized at 140 ° C for 8 seconds by blowing steam at 8 parts by weight / cm2 pressure, and the liquid was further filtered with a 0.22 micron filter (manufactured by Kyno Corporation). The mixture was filtered and dried by spray drying. In addition, this

The average chain length of D-3 was 5.2. <Example 1> (Liver perfusion test)

1) Experimental animal and isolated liver perfusion method

Rats were purchased from Sprague-Dawley (SD) male rats (4 weeks old, weighing 70-80 g) from Kudo Co., Ltd. (Kumamoto). After preliminary breeding for 6 to 10 days, the animals are divided into 4 groups: casein group, soy protein group, soy protein enzyme decomposition group D-1, and soy protein enzyme decomposition group D-3. They were fed. The temperature of the breeding room was maintained at 22 to 24 ° C, and the light period was from 7:00 to 19:00. Feed and deionized water were provided ad libitum. After 4 weeks of feeding, rat isolated liver was perfused. Sprague-Dawley (SD) male rats with an initial weight of 130-140 g were allowed to freely ingest a diet prepared according to AIN76 for 4 weeks, and the liver was isolated and subjected to a perfusion experiment.

The protein content was calculated as nitrogen, casein 20%, soybean protein (Fujipro_R, manufactured by Fuji Oil Co., Ltd.) 19.63%, soybean protein digest D-1 20.18% and soybean protein digest D —3 was added at 19.29%. In addition, 3-cornstarch 15%, DL-methionine 0.3%, cellulose 5%, corn oil 5%, mineral mixture 3.5%, pitamine mixture 1%, choline bitartrate 0.2% are added, and sucrose is added 100% It was prepared so that

In the isolated liver perfusion method, perfusion was performed for 4 hours at a constant temperature of 37 ° C by a recirculation method. The rat is portal vein under Nembutal anesthesia A glass catheter was placed in the upper hepatic vena cava and tied with a thread, and the liver was isolated. The isolated liver was perfused with krebs-Henseleit buffer containing 1.5% albumin, 25% bovine erythrocytes and 25 mM glucose.

During perfusion, 95% oxygen and 5% carbon dioxide were continuously fed into the perfusate using a gas exchange device devised by Hamilton et al. To keep the oxygen concentration constant. 20 ml of oleic acid as an exogenous fatty acid was added at the start of perfusion at 50 ml (100 mM), and thereafter 4.5 ml (90 x mol) per hour was continuously added over time. The perfusion flow rate was adjusted to be around 20 ml. The perfusate was collected every hour, and after removing red blood cells by centrifugation, the amount of lipid secretion and ketone production of the perfusate were measured.

The same amount of fresh perfusate as the collected perfusate was added to the perfusion system again so that the total amount of perfusate became 120 ml. Perfusion usually started between 9:00 and 9:30. The blood was collected before placing the catheter in the portal vein, and after centrifugation the lipid concentration was measured in the supernatant.

2) Analysis of lipid components and ketone bodies

The perfusate from which red blood cells have been removed by centrifugation and the lipid components of the perfused liver are extracted by the method of Folch et al. (J. Folch et al., J. Biol. Chem., 266, 497, 1957). After purification, a certain amount of n Dissolved in 1 hexane. Triglyceride (TG) of this lipid extract was determined by the Fletcher method (Fletcher, MJ, CI in Chem. Acta, 22, 393, 1968), total cholesterol (TC), and the like. And free cholesterol (FC) for Sperry & Webb method (Sperry et al., J. Biol. Cem., 187, 97-106, 1950), and phospholipid (PL) for Rouser method (Rouser et al Lipid

Chromatographic

Analysis, 1011, 99, 1967). The ketone body was measured by an enzymatic method after deproteinizing the perfusate with perchloric acid.

3) Statistical processing

The results were analyzed by performing a one-way analysis of variance and testing for significant differences by Duncan's multiple range test.

(Table 1) Rat weight gain, food intake and liver weight used during perfusion

(Mean ± standard deviation) Symbol abc: Significant difference between different alphabets The amount of food consumption was not significant, but slightly increased in the D-3 group compared to the casein group.

The difference between the D-1 group and the casein group was not clear. Final body weight gain tended to be lower in the soy protein group than in the casein group, but was reversed in the D-1 and D-3 groups. Increase Showed a tendency. On the other hand, liver weight was significantly reduced in the soy protein group, D-group, and D-3 group as compared to the casein group. Table 2) Uptake of exogenous fatty acids

Early: jW mol / l ive r)

(Average value ± standard deviation) It was calculated by subtracting the amount of oleic acid remaining in the perfusate from the amount of oleic acid added to the perfusate. In all groups, exogenous fatty acids uptaked a constant amount of oleic acid up to 4 hours after perfusion. No difference was observed in the uptake of exogenous fatty acids among the four groups. This suggests that changes in lipid parameters caused by perfusion are caused by differences in the quality of dietary proteins after fatty acid uptake. (Table 3) Formation of ketone bodies

(Unit: imol / liver)

(Average value ± standard deviation) Symbol abc Significant difference between different alphabets. The production of ketone bodies increased by a certain amount over time in all groups until the fourth hour. On the other hand, the rat livers of the soy protein group and the peptide intake group (D-1, D-2) tended to increase the production of ketone bodies as compared to the casein group at any time. Especially in the purified D-3 group, the increase was significant at 4 hours compared to the casein group. Thus, the D-3 group was found to enhance trioxidation in the liver mitochondrial fraction.

(Table 4) Ratio of hydroxybutyric acid Zacetoacetic acid

(Average soil standard deviation) Symbol ab c Significant difference between different alphabets Hydroxyacetic acid Zacetoacetic acid ratio is liver mitochondrial It has been shown to show the oxidation and reduction states of the leach fraction, but the ratio of hydroxyacetic acid and Zacetoacetic acid is higher in the soybean protein group, D-1 group, and D-3 group than in the casein diet group It showed a tendency. These results indicate that the oxidation / reduction state in the mitochondrial fraction has shifted to the oxidation state.

5) Liver lipid concentration after perfusion

(Table position: jUmol / g liver;

(Average soil standard deviation) Symbol abc Significant difference between different alphabets. Triglyceride (TG) concentration in the liver was significantly lower in the soy protein group, D-1 group and D-3 group than in the casein group. Total cholesterol (TC) levels were significantly lower in the soy protein group than in the casein group. The results were similar between the D-3 group and the Casein group. The ester content% was significantly lower in the soybean protein group than in the casein group. No clear differences in phospholipid (PL) levels were observed between the groups. (Table 6) Secretion of TG by the liver

(Tabletop: imol / liver)

(Average soil standard deviation) Symbol abc Significant difference between different alphabets TG secretion by the liver at any time at the start of perfusion

The tendency was to decrease in the D-1 group and the D-3 group, and it was largest and significantly decreased in the D-3 group after 4 hours. Table 7) Total cholesterol secretion by the liver

(Unit: mol / liver)

(Average soil standard deviation) Symbol abc Significant difference between different alphabets Total cholesterol secretion did not show any difference in each group.

<Production Example 3> (Method for producing enzyme-decomposed product of soybean protein)

The following Example Soy Enzyme Decomposition D-1 Isolated soy protein (Fuji Oil Co., Ltd., “New Fuji Pro

—R ”) 30 parts by weight of a 9% aqueous solution of pH 7.0, and hydrolyzed at 50 ° C for 5 hours by reacting with 0.6 parts by weight of a proteolytic enzyme (“ Protin AC — 10 ”, manufactured by Daiwa Kasei Co., Ltd.) After decomposition (15% TCA solubility: 85%), this solution was blown with 8 kg / cm ² pressure steam, sterilized at 140 ° C for 7 seconds, and powder-dried by spray drying. The average chain length of HD-1 was 8.0.

<Production Example 4> (Method for producing enzyme-decomposed product of soybean protein)

The following Example Soybean enzyme digest D-3

Isolate soy protein (Fuji Oil Co., Ltd., "New Fujipro-R") 30 parts by weight of 9% aqueous solution of pH 7.0, and proteolytic enzyme (Daiwa Kasei Co., Ltd., "Protin AC-10") ) And hydrolyze at 50 ° C for 5 hours (15% TCA solubility 85%), and then centrifuge at 100 liters Z in a high-speed centrifuge (SB-7, WESTFALIA SEPARATOR) capable of continuous processing. The sediment component generated by adjusting the liquid sending speed was separated and removed. The obtained supernatant solution was sterilized by blowing steam at a pressure of 8 kg / cm for 7 seconds at 140 ° C. The solution was then filtered through a 0.22 micron (Kunoichi Co., Ltd.) filter and dried by spray drying to dry the powder. I let it. The average chain length of this LD-3 was 7.0.

Adjust the pH of the enzymatic digest solution to pH 4.5 with hydrochloric acid in the same manner as the hydrolyzed solution at pH 4.5, and feed it to a high-speed centrifuge (SB-7, manufactured by WESTFALIA SEPARATOR) capable of continuous processing at a rate of 100 liters / hour. The resulting sediment components were separated and removed. After adjusting the pH of the solution to 7.0 with Na〇H, the pressure was 8 kg / cm2. The solution was sterilized at 0 ° C. for 7 seconds, and the solution was filtered through a 0.22 micron filter (manufactured by Kyuno Co., Ltd.) and powder-dried by spray drying. The average chain length of this LD-5 was 6.0.

<Example 2> (Test of liver lipid concentration and body fat) 1) Experimental animal and isolated liver perfusion method

Rats were purchased from Sprague-Dawley (SD) male rats (4 weeks old, weighing 70-80 g) from Kudo Co., Ltd. (Kumamoto). After pre-breeding for 6 to 10 days, it is divided into 5 groups: casein group, soy protein group, soy protein enzyme decomposition group HD-1, soy protein enzyme decomposition LD-3, and soy protein enzyme decomposition LD-5 They were fed the following diets for 4 weeks. The temperature of the breeding room was maintained at 22 to 24 ° C, and the light period was from 7:00 to 19:00. Feed and deionized water were provided ad libitum. After two weeks of feeding, rats were sacrificed by decapitation and ingested liver and adipose tissue. Adipose tissue ingested fat around the kidney and epididymis. The rats were fed Sprague-Dawley (SD) male rats with an initial weight of 130-140 g freely for 2 weeks on feed prepared according to AIN76. In the sample composition, the protein content is 20% casein in terms of nitrogen, soy protein (manufactured by Fuji Pro-R Fuji Oil Co., Ltd.) 19.63%, soy protein digest HD-1 20.18% and soy protein digest 19.29% of LD-3 and 21.71% of LD-5 were added. In addition, 3-—corn starch 15%, DL—methionine 0.3%, cellulose 5%, corn oil 5%, mineral blend Total 3.5%, mixed vitamin 1%, choline bitartrate 0.2% were added, and sucrose was added to make 100%. 2) Lipid components and 3) Statistical processing are as in Example 1. Table 8 shows body weight, food consumption and liver weight.

(Table 8) Rat weight gain, food consumption and liver weight

(Average value of soil standard deviation) Symbol ab: Significant difference between different alphabets No difference was observed in food intake and body weight gain among all groups. Liver weight was significantly lower in the other groups than in the Casein group. Adipose tissue weight around the kidney and epididymis appeared to tend to be slightly lower in the LD-5 group. Table 9 shows the liver lipid concentration. Three

9 {^ -i.: Mg / g liver;

Liver

1

(Mean ± standard deviation) Symbol abc Significant difference between different alphabets TG concentration decreased significantly in all groups compared to Case in group, but decreased most in LD-5 group. TC concentrations were significantly lower in the other groups than in the Casein group, but the soy protein group and HD-1 group were significantly lower. Free cholesterol levels were similarly lower in the other groups than in the Casein group. The ester ratio was significantly lower in the other groups than in the Casein group, and was particularly remarkable in the soy protein group. There was no significant difference in PL concentration in any of the groups.

From the above, it was found that soy peptide produced from soy protein has a strong effect of promoting fatty acid trioxidation in the liver to promote fatty acid degradation and inhibiting secretion of TG synthesized in the liver. . '' Industrial applicability

According to the present invention, the amount of fatty acid absorption itself is not changed by the experiment of the perfusion system of the liver taken out from the liver, and the fat in the liver is not changed. By promoting metabolic metabolism, it is possible to reduce the accumulation and secretion of tridaliceride in the liver.

In other words, symptoms of a disease caused by abnormal lipid metabolism in the liver according to the present invention (eg, a disease caused by excessive accumulation of triglycerides in the body: risk of fatty liver, cirrhosis of the liver, etc.). It has become possible to reduce and prevent harm.

The enzyme-decomposed product of soybean protein of the present invention is also effective as an active ingredient of a lipid metabolism improving agent as an extremely safe and functional material (including not only for pharmaceuticals but also for foods).

Claims

The scope of the claims

1. An agent for improving lipid metabolism in the liver, which contains an enzymatic degradation product of soybean protein as an active ingredient.

2. The agent for improving lipid metabolism in the liver according to claim 1, wherein the lipid metabolism promotes oxidation in the liver to reduce the tridaliceride content in the liver.

3. The hepatic lipid metabolism-improving agent according to claim 1 or claim 2, wherein lipid metabolism suppresses secretion of triglyceride from the liver.

4. The agent for improving lipid metabolism in the liver according to any one of claims 1 to 3, wherein the enzyme digest of soy protein has an average peptide chain length of 2 to 20.

5. The hepatic lipid metabolism-improving agent according to any one of claims 1 to 4, wherein the enzyme hydrolyzate of soy protein has an average peptide chain length of 5 to 10.